Pro-(IL-18) and Anti-(IL-10) Inflammatory Promoter Genetic Variants (Intrinsic Factors) with Tobacco Exposure (Extrinsic Factors) May Influence Susceptibility and Severity of Prostate Carcinoma: A Prospective Study

  • Dwivedi, Shailendra (Department of Biochemistry, All India Institute of Medical Sciences) ;
  • Singh, Sarvesh (Department of Pharmacology and Therapeutics, King George Medical University) ;
  • Goel, Apul (Department of Urology, King George Medical University) ;
  • Khattri, Sanjay (Department of Pharmacology and Therapeutics, King George Medical University) ;
  • Mandhani, Anil (Department of Urology, Sanjay Gandhi Post Graduate Institute of Medical Sciences) ;
  • Sharma, Praveen (Department of Biochemistry, All India Institute of Medical Sciences) ;
  • Misra, Sanjeev (Department of Surgical Oncology, All India Institute of Medical Sciences) ;
  • Pant, Kamlesh Kumar (Department of Pharmacology and Therapeutics, King George Medical University)
  • Published : 2015.04.29


Background: It has been hypothesized that IL-18 (pro-) and IL-10 (anti-) inflammatory genetic variants at -607 C/A-137G/C and -819C/T,-592C/A, respectively, may generate susceptibility and severity risk with various modes of tobacco exposure in prostate carcinoma (PCa) patients. IL-18 is a pro-inflammatory cytokine expressed on various cells including prostate gland elements, and is a key mediator of immune responses with anti-cancerous properties. IL-10 is an anti-inflammatory cytokine that is associated with tumour malignancy which causes immune escape. Materials and Methods: The present study was conducted with 540 subjects, comprising 269 prostate carcinoma patients and 271 controls. Genotyping was performed by PCR-RFLP and confirmed by real time PCR probe-based methods. Results: The findings indicated that the mutant heterozygous and homozygous genotype CC and GC+CC showed significant negative associations (p=0.01, OR=0.21; 95% CI: 0.08-0.51 and p=0.011, OR=0.43; 95% CI: 0.22-0.81, respectively) thus, less chance to be diagnosed as cancer against GG genotype of tobacco smoking patients. In addition, a heterozygous GC genotype at the same locus of IL-18 pro-inflammatory cytokine may aggravate the severity (OR=2.82; 95%CI 1.09-7.29 :p=001) so that patients are more likely to be diagnosed in advanced stage than with the GG wild homozygous genotype. Our results also illustrated that anti-inflammatory cytokine (IL-10) genetic variants, although showing no significant association with susceptibility to cancer of the prostate, may gave profound effects on severity of the disease, as -819 TC (OR=4.60; 95%CI 1.35-15.73), and -592 AC (OR=5.04; 95%CI 1.08-25.43) of IL-10 in tobacco chewers and combined users (both chewers and smokers) respectively, are associated with diagnosis in more advanced stage than with other variants. Conclusions: We conclude that promoter genetic variants of IL-18 and IL-10 with various modes of tobacco exposure may affect not only susceptibility risk but also severity in prostate cancer.


Prostate carcinoma;tobacco smokers/chewers;combined users;IL-18;IL-10;genetic polymorphisms


Supported by : Indian Council of Medical Research


  1. Aggarwal BB, Vijayalekshmi RV, Sung B (2009). Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res, 15, 425-30.
  2. Asadullah K, Sterry W, Volk HD (2003). Interleukin-10 therapy--review of a new approach. Pharmacol Rev, 55, 241-69.
  3. Bae JM, Li ZM, Shin MH, et al (2013). Cigarette smoking and prostate cancer risk: negative results of the Seoul male cancer cohort study. Asian Pac J Cancer Prev, 14, 4667-9.
  4. Balkwill F (2009). Tumour necrosis factor and cancer. Nat Rev Cancer, 9, 361-71.
  5. Berger CL, Tigelaar R, Cohen J, et al (2005). T-cell lymphoma:malignant proliferation of T-regulatory cells. Blood, 105, 1640-7.
  6. Bostwick DG, Burke HB, Djakiew D, et al (2004). Human prostate cancer risk factors. Cancer, 101, 2371-490.
  7. Chen FC, Zhang F, Zhang ZJ, et al (2013). Tumor necrosis factor-$\alpha$ gene polymorphisms and risk of oral cancer:evidence from a meta-analysis. Asian Pac J Cancer Prev, 14, 7243-9.
  8. Colotta F, Allavena P, Sica A, et al (2009). Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis, 30, 1073-1.
  9. Das M, Sharma SK, Sekhon GS, et al (2014). Promoter methylation of MGMT gene in serum of patients with esophageal squamous cell carcinoma in North East India. Asian Pac J Cancer Prev, 15, 9955-60.
  10. Dwivedi S, Singh S, Gupta V, et al (2011a). Serum Interleukin-18 levels at a base line could serve as a better differentiating factor for carcinoma prostate and benign prostate hyperplasia -A study in north Indian population. Indian Stream Res J, 1,
  11. Dwivedi S, Goel A, Natu SM, et al (2011b). Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study. Asian Pac J Cancer Prev, 12, 1843-8.
  12. Dwivedi S, Goel A, Mandhani A, et al (2012). Tobacco exposure may enhance inflammation in prostate carcinoma patients:an explorative study in North Indian population. Toxicol Int, 19, 310-8.
  13. Dwivedi S, Shukla KK, Gupta G, et al (2013). Non-invasive biomarker in prostate cancer: a novel approach. Indian J Clin Biochem, 28, 107-9.
  14. Dwivedi S, Goel A, Khattri S, et al (2014). Tobacco exposure by various modesmay alter pro-inflammatory (IL- 12) and anti-inflammatory (IL-10) levels and affects the survival of prostate carcinoma patients: an explorative study in North Indian population. BioMed Res Int, 2014, 158530
  15. Dwivedi S, Goel A, Khattri S, et al (2015). Aggravation of inflammation by smokeless tobacco in comparison of smoked tobacco. Ind J Clin Biochem, 30, 117-9.
  16. Ebadi N, Jahed M, Mivehchi M, et al (2014). Interleukin-12 and interleukin-6 gene polymorphisms and risk of bladder cancer in the Iranian population. Asian Pac J Cancer Prev, 15, 7869-73.
  17. Fiorentino DF, Bond MW, Mosmann TR (1989). Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med, 170, 2081-95.
  18. Giedraitis V, He B, Huang WX, et al (2001). Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol, 112, 146-52
  19. Islami F, Moreira DM, Boffetta P, et al (2014). A systematic review and meta-analysis of tobacco use and prostate cancer mortality and incidence in prospective cohort studies. Eur Urol, 66, 1054-64.
  20. Lee HR, Jeung EB, Cho MH, et al (2013). Molecular mechanism(s) of endocrine-disrupting chemicals and their potent oestrogenicity in diverse cells and tissues that express oestrogen receptors. J Cell Mol Med, 17, 1-11.
  21. Liu Y, Lin N, Huang L, Xu Q, Pang G. Genetic polymorphisms of the interleukin-18 gene and risk of prostate cancer. DNA Cell Biol, 26, 613-8.
  22. Malakar M, Devi KR, Phukan RK, et al (2014). p53 codon 72 polymorphism interactions with dietary and tobacco related habits and risk of stomach cancer in Mizoram, India. Asian Pac J Cancer Prev, 15, 717-23.
  23. Mantovani A (2005). Cancer: inflammation by remote control. Nature, 435, 752-3.
  24. Moore KW, Malefyt R de Waal, Coffman RL, et al (2001). Interleukin-10 and the interleukin-10 receptor. Ann Rev Immunol, 1, 683-65
  25. Moore MA, Tsuda H (2002). Smoking-related research in the Asian-Pacific countries. Asian Pac J Cancer Prev, 3, 291-304.
  26. Nelles JL, Hu WY, Prins GS (2011). Estrogen action and prostate cancer. Expert Rev Endocrinol Metab, 6, 437-451.
  27. Nong LG, Luo B, Zhang L,et al (2009). Interleukin-18 gene promoter polymorphism and the risk of nasopharyngeal carcinoma in a Chinese population. DNA Cell Biol, 28, 507-13.
  28. Pleasance ED, Stephens PJ, O'Meara S, et al (2010). A small cell lung cancer genome with complex signatures of tobacco exposure. Nature, 463, 184-90.
  29. Rius J, Guma M, Schachtrup C, et al (2008). NF-kappaB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1alpha. Nature, 453, 807-11.
  30. Shi YY, He L (2005). SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res, 15, 97-8.
  31. Sobti RC, Shekari M, Tamandani DM, et al (2008). Association of interleukin-18 gene promoter polymorphism on the risk of cervix carcinogenesis in north Indian population. Oncol Res, 17, 159-66.
  32. Tatsumi T, Gambotto A, Robbins PD, et al (2002) .Interleukin-18 gene transfer expends the repertoire of antitumor TH1-type immunity elicited by dendritic cell- based vaccines in association with enhanced therapeutic efficacy. Cancer Res, 62, 5853-8.
  33. Tysome JR, Lemoine NR, Wang Y (2013). Update on oncolytic viral therapy - targeting angiogenesis. Onco Targets Ther, 6, 1031-40.
  34. Wong JL, Berk E, Edwards RP, et al (2013). IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res, 73, 4653-62.
  35. Xia D, Li F, Xiang J (2004). Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity. Cancer Biother Radio, 19, 322-30.

Cited by

  1. Diseases and Molecular Diagnostics: A Step Closer to Precision Medicine vol.32, pp.4, 2017,
  2. Functional genetic variability at promoters of pro-(IL-18) and anti-(IL-10) inflammatory affects their mRNA expression and survival in prostate carcinoma patients: Five year follow-up study vol.75, pp.15, 2015,
  3. Effect of Severity of Opiate Use on Cardiometabolic Profile of Chronic Opiate Dependents of Western Rajasthan pp.0974-0422, 2018,